Want to join the conversation?
$PFE said that as per its agreement with RPI, a subsidiary of Royalty Pharma, RPI will fund up to $300MM in development costs related to certain Phase III clinical trials of $PFE's breast cancer drug Ibrance. For up to 3 years post Hospira acquisition, $PFE expects costs to be $1Bil, excluding costs of $215MM in 2015 for in-process R&D rights.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.